Unrecognized sexual dysfunction in gay and bisexual men after prostate cancer treatment: the antecedents and impact of anodyspareunia

Author:

Wheldon Christopher W1,Bates Alex J2ORCID,Polter Elizabeth J2,Rosser B R Simon2,Kapoor Aditya3,Talley Kristine M C4,Haggart Ryan5,Kohli Nidhi6,Konety Badrinath R7,Mitteldorf Darryl8,Ross Michael W9,West William10,Wright Morgan2

Affiliation:

1. College of Public Health, Temple University Department of Social and Behavioral Sciences, , Philadelphia, P A United States

2. University of Minnesota Division of Epidemiology and Community Health, School of Public Health, , Minneapolis, Minnesota , United States

3. Trinity Teleradiology Services Department of Radiology, , Vancouver, BC , Canada

4. University of Minnesota School of Nursing School Adult and Gerontological Health, , Minneapolis, Minnesota , United States

5. University of Minnesota Department of Urology, , Minneapolis, Minnesota , United States

6. University of Minnesota Department of Educational Psychology, , Minneapolis, Minnesota , United States

7. Rush Medical College Department of Urology, , Chicago, Illinois

8. Malecare Cancer Support , New York, New York , United States

9. University of Minnesota Medical School Department of Family Medicine and Community Health, , Minneapolis, Minnesota , United States

10. University of Minnesota Department of Writing Studies, , Minneapolis, Minnesota , United States

Abstract

AbstractBackgroundAnodyspareunia may be an adverse outcome of prostate cancer (PCa) treatment for gay, bisexual, and other men who have sex with men (GBM).AimThe aims of this study were to (1) describe the clinical symptoms of painful receptive anal intercourse (RAI) in GBM following PCa treatment, (2) estimate the prevalence of anodyspareunia, and (3) identify clinical and psychosocial correlates.MethodsThis was a secondary analysis of baseline and 24-month follow-up data from the Restore-2 randomized clinical trial of 401 GBM treated for PCa. The analytic sample included only those participants who attempted RAI during or since their PCa treatment (N = 195).OutcomesAnodyspareunia was operationalized as moderate to severe pain during RAI for ≥6 months that resulted in mild to severe distress. Additional quality-of-life outcomes included the Expanded Prostate Cancer Index Composite (bowel function and bother subscales), the Brief Symptom Inventory–18, and the Functional Assessment of Cancer Therapy–Prostate.ResultsOverall 82 (42.1%) participants reported pain during RAI since completing PCa treatment. Of these, 45.1% experienced painful RAI sometimes or frequently, and 63.0% indicated that the pain was persistent. The pain at its worst was moderate to very severe for 79.0%. The experience of pain was at least mildly distressing for 63.5%. Painful RAI worsened for a third (33.4%) of participants after completing PCa treatment. Of the 82 GBM, 15.4% were classified as meeting criteria for anodyspareunia. Antecedents of anodyspareunia included a lifelong history of painful RAI and bowel dysfunction following PCa treatment. Those reporting symptoms of anodyspareunia were more likely to avoid RAI due to pain (adjusted odds ratio, 4.37), which was negatively associated with sexual satisfaction (mean difference, −2.77) and self-esteem (mean difference, −3.33). The model explained 37.2% of the variance in overall quality of life.Clinical ImplicationsCulturally responsive PCa care should include the assessment of anodyspareunia among GBM and explore treatment options.Strengths and LimitationsThis is the largest study to date focused on anodyspareunia among GBM treated for PCa. Anodyspareunia was assessed with multiple items characterizing the intensity, duration, and distress related to painful RAI. The external validity of the findings is limited by the nonprobability sample. Furthermore, the cause-and-effect relationships between the reported associations cannot be established by the research design.ConclusionsAnodyspareunia should be considered a sexual dysfunction in GBM and investigated as an adverse outcome of PCa treatment.

Funder

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Urology,Reproductive Medicine,Endocrinology,Endocrinology, Diabetes and Metabolism,Psychiatry and Mental health

Reference35 articles.

1. Sexual function in patients treated with stereotactic radiotherapy for prostate cancer: a systematic review of the current evidence;Loi;J Sex Med,2019

2. Radical prostatectomy versus deferred treatment for localised prostate cancer;Vernooij;Cochrane Database Syst Rev,2020

3. Sexual dysfunction in gay and bisexual prostate cancer survivors: a concept analysis;Mitchell;J Homosex

4. A systematic review of Expanded Prostate Cancer Index Composite (EPIC) quality of life after surgery or radiation treatment;Lee;Can J Urol,2015

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3